Put our insights to work for your brand by accessing our newest solution, HCP Message Monitor. https://ow.ly/mTfH50SAK1p
MMIT (Managed Markets Insight & Technology)
Information Services
Yardley, Pennsylvania 46,818 followers
About us
For nearly two decades MMIT has been solely focused on solving the “what and why” of drug coverage, and has been a trusted, go-to-market partner to pharma companies, payers and providers. We believe that patients who need lifesaving treatments shouldn’t face delays because accessing drugs can be confusing. As the leading provider of market access data, analytics and insights, our expert teams of clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions. Divisions of MMIT include AIS Health, creator of the Directory of Health Plans and leading healthcare publications; Zitter Health Insights, a preeminent provider of market access insights and solutions for specialty drugs; RJ Health, the market leader in pricing and coding solutions for infusion drugs covered under the medical benefit; and The Dedham Group, a U.S. market access oncology and specialty therapeutics consultancy offering research, data analytics and strategy formulation services to the life sciences industry.
- Website
-
http://www.mmitnetwork.com
External link for MMIT (Managed Markets Insight & Technology)
- Industry
- Information Services
- Company size
- 201-500 employees
- Headquarters
- Yardley, Pennsylvania
- Type
- Privately Held
- Specialties
- Formulary, Policy & Restriction Transparency, Mobile Formulary Search Application, Launch Commercialization Guidance, and Formulary Management & Publishing
Locations
Employees at MMIT (Managed Markets Insight & Technology)
Updates
-
The coverage landscape may be stronger for well-established products than pharma companies assume. https://ow.ly/nyb450T50TO This case study details how Peregrine Market Access helped one client grow its market by sharing localized coverage details with physicians via MMIT’s FormTrak solution. Click the link to download your copy. Ryan Collazo, Zach Guarino #Pharma #BioPharma #MarketAccess
-
Pharma companies are approaching market access planning early, using real-world data and AI. https://ow.ly/PrMA50SzNIM In Life Science Leader, MMIT and The Dedham Group experts explain why increased financial pressures have resulted in greater investment in market access. #MarketAccess #Pharma #PharmaCompanies
-
Did you know over half of payers anticipate more PBMs are likely to begin to pursue vertical integration, further expanding access to biosimilars? See this insight from our MMIT Rapid Event Primer analysts: https://ow.ly/P7Gb50TemVE.
-
Do you need a primer on #MarketAccess? In this free ebook for #pharma, you can learn how to understand and influence payer policies, improve coverage and communicate with HCPs. https://ow.ly/Tuit50SUYVu
-
Disease state education isn’t just for first-to-market therapies. https://ow.ly/mex250SUY5E In BioPharma Dive, Dr. Shrinal Patel and Carolyn Zele share how and why pharma manufacturers should invest in physician education in peer-to-peer networks. #MarketAccess #PharmaManufacturers #Pharma #Physicians
-
The rise of private-label pharmaceutical distributors is changing biosimilar adoption and making contracting more complex. https://ow.ly/IiBO50T1zVh MMIT’s Benjamin Hinton II, PharmD, RPh, discusses the influence of major payers/PBMs and the loss of interchangeability as a differentiator in Drug Channels Institute, an HMP Global Company. Click the link in this post to read the article. #PharmacyBenefitManagers #BiosimilarManufacturers #MarketAccess
-
Learn 4 ways pharma is getting creative with physician engagement, from using real-time lab alerts to better tracking for pull-through messaging. https://ow.ly/3uUF50SJGHM
-
MMIT’s Catherine Humphries talks to Harvard researcher Luca Maini about what will happen when the IRA is fully implemented. https://ow.ly/MbCi50SL2j6 Topics include unintended effects of Medicare Part D benefit design, protected class regulations, and how Medicare formularies will likely change after the full implementation of the IRA.
-
There’s a paradigm shift happening in obesity treatment. MMIT’s Autumn Bowman explores what Wegovy’s new cardiovascular indication means for the rest of the GLP-1 agonists and what the state of payer coverage looks like today: https://ow.ly/F9oP50SyY6I.